Helix Biopharma Corp. is focused on developing innovative therapies in the field of immuno-oncology, primarily through its proprietary platform known as DOS47. This patented technology utilizes a naturally occurring enzyme, urease, derived from the jack bean plant, which breaks down urea into ammonia and hydroxyl ions at the site of cancerous tissues. By increasing the pH of the tumor microenvironment, DOS47 aims to counteract the acidic conditions that protect tumors, potentially leading to the programmed cell death of cancer cells. The platform is designed to work as both a monotherapy and in combination with other treatments, including chemotherapy and immunotherapy.

The company's lead candidate, L-DOS47, is an antibody-drug conjugate (ADC) that combines urease with a specialized camelid-derived single domain antibody targeting CEACAM6, a protein often overexpressed in certain cancers. Currently undergoing clinical trials for pancreatic cancer, L-DOS47 exemplifies Helix's strategy of using targeted therapeutics to enhance the efficacy of cancer treatments. The DOS47 platform is versatile, with potential applications across various solid tumors by selecting antibodies that specifically bind to different tumor cell surface receptors, thereby expanding the company's product pipeline in the fight against cancer.

Canada

We are a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47.

DOS47 is our patented oncology platform technology that offers a new and revolutionary approach to the debilitation and destruction of cancer cells.

Helix is led by an experienced Management team with excellent pharmaceutical development expertise and proven business skills. The group is committed in developing novel medicines through DOS47 platform technology.

Helix Biopharma

Company Details